- Meeting abstract
- Open Access
Evaluation of biochemical and reproductive biomarkers on gestational period in immunosuppressed Wistar rats with Cyclosporin
© Schavinski et al. 2015
- Published: 11 November 2015
- High Density Lipoprotein
- Oral Glucose Tolerance Test
- Reproductive Parameter
The pregnancy period involves a lot of biological changes, and the use of medication must be taken with extremely caution, especially because of its implications for maternal and fetal health, involving biochemical and reproductive functions in maternal organism. Also, the Cyclosporin A (CLP) is used to avoid possible rejection of transplanted tissues, being one of most immunosuppressant used.
The objective of this study was to evaluate the effects of immunosuppressive therapy with Cyclosporine A in reproductive and biochemical profile in pregnant Wistar rats.
The rats were randomized into three groups CONT (treated with tap water), CLP1 (treated with Cyclosporin A 15 mg/kg before and during pregnancy) and CLP2 (treated with Cyclosporin A 15 mg/kg before pregnancy), n=8 per group. The body weight, food and water intake, and glucose were measured weekly. On the 17th day of pregnancy it was evaluated the oral glucose tolerance test (OGTT). The reproductive parameters were determined by fertility indices, pregnancy and childbirth. On the last day of pregnancy (day 21), serum biochemical analysis were performed (total protein, cholesterol, triglycerides from high density lipoprotein (HDL) cholesterol and very low density lipoprotein (VLDL). The statistical significance was considered p<0.05.
It was observed a progressive increase in body weight during the pregnancy in all groups compared to the first day. In addition, the continued use of this drug decreased food intake and slightly blood glucose. The reproductive parameters have not changed. The glycemic curve generated by OGTT show the timepoint of 120 min of CLP1 group was increased related to other groups. In biochemical evaluation, serum cholesterol and HDL were unchanged, but the treatment with the drug led increase in protein concentration (CLP2), triglyceride and VLDL (CLP1) and also an increase in ALT activity, AST and reduced (in both groups).
The use of Cyclosporine A during pregnancy has some security for weight gain, lipid metabolism and also maternal insulin action in maternal organism.
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.